Navigation Links
NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
Date:7/22/2008

naproxen 250 mg bid, naproxen 500 mg bid or ibuprofen 600 mg tid (three times daily).

The data from the 111 and 112 studies will complement the results of a 2-week ABPM study with naproxcinod compared to naproxen in hypertensive volunteers (the 104 study), which were presented at the American Heart Association (AHA) in November 2007. They will also complement the Office Blood Pressure Measurements (OBPMs) being collected in each of the pivotal phase 3 OA studies (including the completed 301 study and the ongoing 302 and 303 studies).

Maarten Beekman, Vice President of Clinical Development and Medical Affairs at NicOx commented: "We are very pleased to have fully enrolled these two clinical pharmacology studies and we look forward to their results in the fourth quarter of this year. We believe the timely achievement of this milestone is a testament to the strength of the clinical team we have assembled at NicOx and also reflects the interest of clinical centers and patients in naproxcinod."

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalen
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
11. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   Voalte , the leader in healthcare communication ... million by Ascension Ventures , Cerner Capital, Inc., ... D funding closed on July 27, 2015, bringing the ... in three years. The new capital will ... Voalte. The privately held company grew revenue by 250 ...
(Date:9/1/2015)... SAN DIEGO and BEDFORD, Mass. ... firm Robbins Arroyo LLP is investigating whether ... violated the Securities and Exchange Act of 1934.  ConforMIS ... Image-to-Implant technology platform to develop, manufacture, and sell joint ... fit each patient,s unique anatomy. View this ...
(Date:9/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... the Patent Trial and Appeals Board (PTAB) in response ... filed by a unit of Boston Scientific Corporation, challenging ... 8,359,102 (the ,102 patent). The ,102 patent is one of Nevro,s 55 ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2
... The Gulf Coast Regional Center of Innovation and Commercialization ... receive up to a total of $2.9 million in ...   (Logo:   http://photos.prnewswire.com/prnh/20090604/AQ28157LOGO ) ... TETF program was established by Gov. Perry and the ...
... NCIIA announced this month the winners of the inaugural ... First place and a $10,000 grant for further ... for the HydrEYE CorneOasis Contact Lens, an inexpensive solution ... due to traumatic brain injury.  In place of current ...
Cached Medicine Technology:Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 2Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 3BMEStart Competition Winners Announced 2
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... designed for people to comfortably hold a tablet while reducing the likelihood of it ...
(Date:9/2/2015)... ... , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has ... year. Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; ... 3-year revenue growth rate of 65% sustained its most recent achievement. As an Inc. ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they ... forced to wear a looser fitting shirt with a collar that doesn’t close against the ... between their collar and skin all day because it’s uncomfortable. Now men in suits ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... of hope for visually- impaired patients.Retinal cell transplants can ... possibilities for them. Researchers at the University of Texas, ... a predisposition to blindness.// Experiments showed that the rats ... animals with normal vision. ,This is an ...
... Coffee is a very good stimulant in day to day ... memory performance that happens as the day progresses. During the ... adults compared to late afternoon.// For researchers at the University ... memory performance throughout the day. ,They had about ...
... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...
... Andhra Pradesh chief minister Chandrababu Naidu has set into ... in the port town of Vishakhapatnam. By providing world-class ... to attract global pharmaceutical companies to the city for ... 2005. The ‘Pharma City’ will be developed by private ...
... the disease gradually ended around the world. But stockpiles ... US, Russia and possibly other nations.// Recent fears of ... used to introduce the potentially deadly disease into the ... a potential outbreak. If introduced into America or Europe, ...
... a diet rich in butter and other fats, has led ... staple of the French diet. //Scientists say they have discovered ... known as polyphenols. ,Polyphenols inhibit the production ... Polyphenols in red wine decreases the amount of the peptide ...
Cached Medicine News:
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: